Long-term efficacy of adoptive cell therapy is determined by host CD8+T cells and undermined by lymphodepleting preconditioning

Author:

Figueroa DiegoORCID,Vega Juan Pablo,Hernández-Oliveras Andrés,Gálvez-Cancino Felipe,Ardiles Felipe,Flores Felipe,Hidalgo Sofía,López Ximena,Gonzalez Hugo,Osorio Fabiola,Borgna Vincenzo,Lladser Alvaro

Abstract

AbstractAdoptive T cell therapy (ACT) has demonstrated remarkable efficacy in treating hematological cancers. However, its efficacy against solid tumors remains limited and the emergence of cancer cells that lose expression of targeted antigens often promotes resistance to ACT. Importantly, the mechanisms underlying effective and durable ACT-mediated tumor control are incompletely understood. Here, we show that adoptive transfer of TCR-transgenic CD8+T cells eliminates established murine melanoma tumors, with concomitant accumulation of tumor-infiltrating CD8+T cells exhibiting both progenitor-exhausted and terminally-differentiated phenotypes. Interestingly, host CD8+T cells contributed to ACT-mediated elimination of primary tumors and rejected ACT-resistant melanoma cells lacking the targeted antigen. Mechanistically, ACT induced TNF-α- and cross-presenting dendritic cell-dependent tumor accumulation of endogenous CD8+T cells and effective tumor elimination. Importantly, although lymphodepleting preconditioning enhanced ACT-mediated tumor elimination, it abrogated host antitumor immunity and protection against ACT-resistant melanoma cells. Enrichment of transcriptional signatures associated with TNF-α signaling, cross-presenting dendritic cells and tumor-specific CD8+T cells in human melanoma tumors correlated with favorable responses to ACT and increased survival. Our findings reveal that long-term efficacy of ACT is determined by the interplay between transferred and endogenous CD8+T cells and is undermined by lymphodepleting preconditioning, which ultimately favors ACT resistance.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3